Citations (0)
Keep up to date with the latest research on this topic with citation updates for this article.
Leukemia & Lymphoma
Volume 65, 2024 - Issue 5
Original Articles
A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma
Isha Mola Cytel, Inc., Rotterdam, The NetherlandsCorrespondence[email protected]
https://orcid.org/0009-0009-6366-9178View further author information
https://orcid.org/0009-0009-6366-9178View further author information, , Thomas W. LeBlancb Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC, USAhttps://orcid.org/0000-0002-0546-7895View further author information
https://orcid.org/0000-0002-0546-7895View further author information, , Haitao Chud Pfizer Inc., New York, NY, USAhttps://orcid.org/0000-0003-0932-598XView further author information
https://orcid.org/0000-0003-0932-598XView further author information, , , Alex Schepartd Pfizer Inc., New York, NY, USAhttps://orcid.org/0009-0000-3332-0180View further author information
https://orcid.org/0009-0000-3332-0180View further author information & show all